CSL share price: Current level, director trades and business outlook

Introduction — Why CSL share price matters

The csl share price is closely watched by Australian and global investors because CSL Limited is one of the world’s largest biotech companies. Movements in the company’s stock can reflect developments in vaccine and specialty therapeutics markets, progress in research and development, and the integration of recent acquisitions. For shareholders and prospective investors, up‑to‑date price information and insider activity offer context for assessing near‑term sentiment and longer‑term prospects.

Main body — Current price, insider activity and business context

As of the latest available update, the current share price of CSL Limited (CSL:ASX) is AUD$138.93. The provided sources do not specify the 52‑week high for CSL; that figure is not available in the supplied material.

Director and insider transactions offer additional insight. Reporting requirements of the ASX mean CSL directors must notify changes in shareholding within five business days. Recent director activity recorded in the provided data includes:

• 17/02/26 — Brian McNamee bought +433 shares at $151.56 (conversion of securities).
• 22/08/25 — Brian McNamee bought +312 shares at $216.60 (conversion of securities).
• 21/08/18 — Brian McNamee and Megan Clark each acquired +24 shares at $215.75 under a directors’ share plan.
• Earlier director plan purchases in 2018 and 2017 show periodic participation by executives.

Comparing the current price (A$138.93) with earlier director purchases—some above A$200—indicates the share price has moved materially since those transactions. These trades and the reporting timeline provide a picture of insider engagement but are not, on their own, definitive signals of future performance.

On the business side, Morningstar highlights CSL’s diversified structure: CSL Seqirus (the world’s second‑largest influenza vaccine business, acquired in fiscal 2016), CSL Vifor (an iron deficiency and nephrology business acquired in fiscal 2023) and CSL’s ongoing R&D efforts to broaden its non‑plasma product portfolio. These strategic assets and pipeline progress are central to medium‑term growth prospects.

Conclusion — What this means for readers

The immediate takeaway for readers is that the csl share price sits at A$138.93 based on the supplied information, with insider transactions and strategic acquisitions shaping investor context. Shareholders should monitor ASX announcements for updated director disclosures and the company’s R&D and integration milestones for Seqirus and Vifor. For a complete technical picture—including the 52‑week high—consult live ASX data or official CSL releases, as that specific figure was not provided in the sourced material.